Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Chugai Nets 40%-Plus Profit Rise, but Keeps 3-Year EPS Target; President Nixes Avastin Biosame
Chugai Pharmaceutical saw its profits surge over 40% in January-June, buoyed by new products such as Hemlibra (emicizumab) and Tecentriq (atezolizumab), but President and CEO Tatsuro Kosaka says the company will keep its conservative EPS target unchanged for now amid…
To read the full story
Related Article
- Chugai Closes Book with Double-Digit Earnings Growth on Overseas Sales, Royalties
February 5, 2021
- Chugai Enjoys Higher Earnings in January-September on Hemlibra
October 23, 2020
- Chugai’s Half-Year Earnings Surge on Actemra/Hemlibra Exports
July 28, 2020
- Chugai Ups Core EPS CAGR Target to “Around 30%”: 3-Year Biz Plan
January 31, 2020
- Chugai’s 2019 Earnings Renews Record for Third Year on Hemlibra, Tecentriq
January 31, 2020
- Chugai Notches Up Record Earnings in January-September on Hemlibra, Mainstays
October 25, 2019
- Chugai Running Offensive/Defensive Play towards EPS Growth Goal, Hemlibra Outpaces Target
August 9, 2019
- Chugai Rings Up Record Q1 Earnings on Brisk New Drug Sales
April 25, 2019
- Chugai Plays It Safe with New 3-Year Plan on Consecutive Re-Pricing, Eyes 7-9% Annual EPS Growth
February 1, 2019
- Chugai Renews Record Earnings in 2018 on New Drugs, Exports
February 1, 2019
BUSINESS
- Ultragenyx Seeks Japan Approval for GSDIa Gene Therapy
July 1, 2026
- Specialist Hails Wegovy as “Game Changer” for MASH Treatment
July 1, 2026
- Alfresa Boosts Stake in ENT Cell Sheet Startup
July 1, 2026
- Eisai, UCL Renew Neuroscience Alliance to 2030
July 1, 2026
- Asahi Kasei Nabs Japan Rights to Additional Empaveli Indications
July 1, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…